Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Notes Payables (2016 - 2020)

Zevra Therapeutics' Notes Payables history spans 6 years, with the latest figure at $65.9 million for Q3 2020.

  • For Q3 2020, Notes Payables rose 881.24% year-over-year to $65.9 million; the TTM value through Sep 2020 reached $65.9 million, up 881.24%, while the annual FY2019 figure was $7.0 million, 109.45% up from the prior year.
  • Notes Payables reached $65.9 million in Q3 2020 per ZVRA's latest filing, down from $67.3 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $68.6 million in Q1 2020 to a low of $1.6 million in Q1 2016.
  • Average Notes Payables over 4 years is $18.9 million, with a median of $6.4 million recorded in 2019.
  • Peak YoY movement for Notes Payables: surged 91.12% in 2019, then surged 977.02% in 2020.
  • A 4-year view of Notes Payables shows it stood at $1.9 million in 2016, then surged by 72.52% to $3.3 million in 2018, then skyrocketed by 109.45% to $7.0 million in 2019, then skyrocketed by 844.3% to $65.9 million in 2020.
  • Per Business Quant, the three most recent readings for ZVRA's Notes Payables are $65.9 million (Q3 2020), $67.3 million (Q2 2020), and $68.6 million (Q1 2020).